Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 77Carcinoma, Non-Small-Cell Lung 64Lung Neoplasms 31Hodgkin Disease 13Lymphoma 11Neoplasm Metastasis 10Recurrence 8Lymphoma, Non-Hodgkin 8Prostatic Neoplasms 7Neoplasms 7Adenocarcinoma of Lung 7Uterine Cervical Neoplasms 5Sarcoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Mesothelioma, Malignant 4Lymphoma, Large B-Cell, Diffuse 4Breast Neoplasms, Male 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Burkitt Lymphoma 3Brain Neoplasms 3Waldenstrom Macroglobulinemia 2

Interventions

apatinib 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Triple-Negative Breast Cancer × Vinorelbine × Clear all
NCT03254654 2022-04-20

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Fudan University

Phase 2 Completed
66 enrolled
Breast

Advanced Triple-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡